SecBot SecBot
8-K ·Filed Aug 10, 2026

SLN

Silence Therapeutics plc
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001193125-26-341240
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Phase 2 SANRECO topline readout for divesiran (PV) expected in August 2026 is the dominant catalyst. The narrowing loss and $72.1M cash position suggest manageable burn, but the company remains pre-commercialization. Traders should position for binary outcome at data readout; if positive, could unlock partner interest and re-rate the stock. If negative, the stock likely retraces to pre-pipeline-optimism levels.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.43
T+0 close · Aug 10, 2026 · via day close
Latest settled
+28.19%
T+60 · $19.78
Vs SPY
+30.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $15.43entry
  2. T+1 · 3mo ago −4.60%α −4.28% · $14.72
  3. T+5 · 3mo ago −7.00%α −6.95% · $14.35
  4. T+20 · 2mo ago −11.28%α −10.36% · $13.69
  5. T+60 · 14d ago +28.19%α +30.61% · $19.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M loss in Q2 2025 and ahead of the $0.11 consensus. Cash burn slowed as R&D costs dropped 48% YoY to $9.1M. The key catalyst is the upcoming Phase 2 SANRECO topline readout for divesiran in polycythemia vera expected in August 2026, which will determine the stock's near-term trajectory.

Key Financial Metrics

EPS
−$0.09
est −$0.11 · +18.2%
Revenue
$224.0K
est $876.0K · -74.4%
Rating
in line

Key Facts

  • Net loss of $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025, narrower loss beats consensus of $0.11 loss
  • Revenue $0.2M vs $0.4M in Q2 2025 (AstraZeneca collaboration), no consensus revenue figure available for comparison
  • Cash and cash equivalents $72.1M as of June 30, 2026, up from $11.3M at Dec 31, 2025 (no new financings cited; likely reflects timing of R&D benefit receivable and cash burn)
  • R&D expenses fell 48% YoY to $9.1M (from $17.6M) due to zerlasiran Phase 3 readiness completion and reduced personnel costs
  • Phase 2 SANRECO trial (divesiran) for polycythemia vera patient dosing completed June 2026; topline results on-track for August 2026, binary catalyst
  • SLN312 (AZD1705) Phase 1 results presented at EAS 2026; two preclinical programs (SLN365, SLN098) targeting IND filing in 2027
  • No guidance or revenue/earnings estimates provided for upcoming periods

Financial Impact

Narrower-than-expected loss of $12.3M vs consensus EPS of $0.11 loss (approximately $15.4M), beats on EPS but revenue was less than half of prior quarter's $0.4M; cash position $72.1M provides runway through upcoming Phase 2 catalyst

net_losscash_positionr&d_expenses

Risk Factors

  • Phase 2 SANRECO trial failure or underwhelming efficacy would materially depress the stock given divesiran is the lead candidate
  • Revenue from AstraZeneca collaboration is minimal and unpredictable; company is entirely dependent on pipeline advancement
  • No approved products; ongoing net losses with no clear path to profitability without a partnership or commercialization event
  • Cash burn of ~$12-15M/quarter implies roughly 4-5 quarters of runway at $72.1M; may need to raise capital if pipeline timelines slip

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-341240
Document: d162225d8k.htm0001193125-26-341240
Document: 0001193125-26-341240-index-headers.html0001193125-26-341240
Document: 0001193125-26-341240-index.html0001193125-26-341240
Document: 0001193125-26-341240.txt0001193125-26-341240
8-K Data (Synthetic)0001193125-26-341240

Track record

15 reports on SLN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026